University of Pennsylvania Inks Deal with Passage Bio for Gene Therapy Rights Involving Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A)

University of Pennsylvania Inks Deal with Passage Bio for Gene Therapy Rights Involving Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A)

The University of Pennsylvania (Penn) and its Gene Therapy Program (GTP) has licensed its sixth therapy to brand new start-up biotech venture Passage Bio, a developer of gene therapies for rare monogenic CNS diseases. The deal includes a preclinical treatment for...

Pin It on Pinterest